Generic Name and Formulations:
Sodium hyaluronate 22mg/mL; viscoelastic soln for intra-articular inj.
Indications for MONOVISC:
Treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy or simple analgesics (eg, acetaminophen).
Remove synovial fluid or effusion before inj. Give as a single intra-articular inj. 4mL in one knee only. If bilateral treatment: use one syringe in each knee.
≤21yrs: not established.
Gram (+) bacterial protein allergy. Infections or skin diseases in area of inj site/joint. Systemic bleeding disorders.
Avoid strenuous or prolonged weight-bearing activities within 48hrs following inj. Pregnancy, nursing mothers: not established.
Avoid use of disinfectants containing quaternary ammonium salts; hyaluronan can precipitate in their presence.
Arthralgia, joint swelling, inj site pain.
Single-use syringe (4mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma